Search Results - "Belleli, Rossella"

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression by Herbst, Roy, Jassem, Jacek, Abogunrin, Seye, James, Daniel, McCool, Rachael, Belleli, Rossella, Giaccone, Giuseppe, De Marinis, Filippo

“…In the absence of head-to-head trials of first-line treatments for metastatic non-small cell lung cancer (NSCLC), synthesis of available evidence is needed. We…”
Get full text

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy by Glover, Sarah J, Eastell, Richard, McCloskey, Eugene V, Rogers, Angela, Garnero, Patrick, Lowery, Jonathan, Belleli, Rossella, Wright, Timothy M, John, Markus R

“…Abstract Teriparatide, a parathyroid hormone analogue, is a potent anabolic treatment for postmenopausal osteoporosis. Studies have shown that teriparatide…”
Get full text

Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects by Séchaud, Romain, Robeva, Anna, Belleli, Rossella, Balez, Sebastien

“…Deferasirox is a novel iron chelator formulated as tablets for dispersion (suspension) for once‐a‐day oral administration. The current study evaluated the…”
Get full text

Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective by Yip, Chui-ying, Greystoke, Alastair, Abogunrin, Seye, Belleli, Rossella, Di Maio, Danilo, Rouse, Peter, Jovanoski, Nick

“…•Cost-effective therapy for NSCLC is central to value-based care.•This study evaluated the cost-effectiveness of adjuvant atezolizumab in the UK.•Adjuvant…”
Get full text

Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence by Bowes, Kathleen, Jovanoski, Nick, Brown, Audrey E., Di Maio, Danilo, Belleli, Rossella, Chadda, Shkun, Abogunrin, Seye

“…Approximately 10–50% of patients treated for early-stage (I–III), resectable non-small cell lung cancer (eNSCLC) will develop locoregional recurrence. There is…”
Get full text

Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC) by Jovanoski, Nick, Abogunrin, Seye, Di Maio, Danilo, Belleli, Rossella, Hudson, Pollyanna, Bhadti, Sneha, Jones, Libby G.

“…Background Approximately 2 million new cases and 1.76 million deaths occur annually due to lung cancer, with the main histological subtype being non-small cell…”
Get full text

Regulatory watch: Efficiency indicators for new drugs approved by the FDA from 2003 to 2013 by Belleli, Rossella, Fisch, Roland, Szucs, Thomas D

Get full text

Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence by Jovanoski, Nick, Bowes, Kathleen, Brown, Audrey, Belleli, Rossella, Di Maio, Danilo, Chadda, Shkun, Abogunrin, Seye

“…Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients. Review of long-term survival and quality-of-life after…”
Get full text

A nonparametric method to detect increased frequencies of adverse drug reactions over time by Heimann, Günter, Belleli, Rossella, Kerman, Jouni, Fisch, Roland, Kahn, Joseph, Behr, Sigrid, Berlin, Conny

“…Signal detection is routinely applied to spontaneous report safety databases in the pharmaceutical industry and by regulators. As an example, methods that…”
Get full text

Efficiency indicators for new drugs approved by the FDA from 2003 to 2013 by Belleli, Rossella, Fisch, Roland, Szucs, Thomas D.

Get full text

A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA by Do, Thy P., Seetasith, Arpamas, Belleli, Rossella, Schlienger, Raymond G., Corda, Stefano, Burudpakdee, Chakkarin, Streefkerk, Hendrik J., Behr, Sigrid

“…Introduction Real-world evidence on the risk of angioedema associated with angiotensin-converting enzyme inhibitors (ACEIs) in patients with heart failure (HF)…”
Get full text

Abstract CT239: IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC by Wang, Jie, Fan, Yun, Fang, Jian, He, Jianxing, Liu, Yunpeng, Tao, Min, Altorki, Nasser, Felip, Enriqueta, Wakelee, Heather, Vallieres, Eric, Belleli, Rossella, McNally, Virginia, Bennett, Elizabeth, Gitlitz, Barbara J., Zhou, Caicun

“…Background The Phase III IMpower010 study (NCT02486718) met its primary endpoint at the disease-free survival (DFS) interim analysis (IA; clinical cutoff: Jan…”
Get full text

AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women by John, Markus R, Harfst, Evita, Loeffler, Juergen, Belleli, Rossella, Mason, June, Bruin, Gerard J.M, Seuwen, Klaus, Klickstein, Lloyd B, Mindeholm, Linda, Widler, Leo, Kneissel, Michaela

“…Abstract Antagonism of the calcium-sensing receptor in the parathyroid gland leads to parathyroid hormone (PTH) release. Calcilytics are a new class of…”
Get full text

Assessing switchability for biosimilar products: modelling approaches applied to children's growth by Belleli, Rossella, Fisch, Roland, Renard, Didier, Woehling, Heike, Gsteiger, Sandro

“…The present paper describes two statistical modelling approaches that have been developed to demonstrate switchability from the original recombinant human…”
Get full text

ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans by John, Markus R, Widler, Leo, Gamse, Rainer, Buhl, Thomas, Seuwen, Klaus, Breitenstein, Werner, Bruin, Gerard J.M, Belleli, Rossella, Klickstein, Lloyd B, Kneissel, Michaela

“…Abstract Parathyroid hormone (PTH), when injected daily as either the intact hormone PTH(1–84) or the active fragment PTH(1–34) (teriparatide), is an…”
Get full text

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major by Galanello, R, Piga, A, Forni, GL, Bertrand, Y, Foschini, ML, Bordone, E, Leoni, G, Lavagetto, A, Zappu, A, Longo, F, Maseruka, H, Hewson, N, Sechaud, R, Belleli, R, Alberti, D

“…Ospedale Regionale Microcitemie, Dipartimento di Scienze Biomediche e Biotecnologie, Universita di Cagliari, Via Jenner s/n, 09121 Cagliari, Italy…”
Get full text

Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen by Galanello, Renzo, Piga, Antonio, Cappellini, Maria Domenica, Forni, Gian Luca, Zappu, Antonella, Origa, Raffaella, Dutreix, Catherine, Belleli, Rossella, Ford, John M., Rivière, Gilles-Jacques, Balez, Sébastien, Alberti, Daniele, Séchaud, Romain

“…Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high…”
Get full text